Painless Local Anaesthesia With Bicarbonate Admixture

NCT ID: NCT03238625

Last Updated: 2017-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-08-01

Study Completion Date

2017-10-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study examines whether the injection of local anesthesia mixed with sodium bicarbonate in the ratio of 3:1 creates a less burning sensation and is as effective regarding the anesthetic effect as in the ratio of 9:1.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Therefore the investigators compare two groups with 24 healthy individuals in each group in a cross-over study. One group receives four injections (two in each forearm) and one group receives only two injections (one in each forearm)

The four injections of group 1 are:

* IMP1: Lidocaine and sodium bicarbonate ratio 3:1
* IMP 2: Lidocaine and sodium bicarbonate ratio 9:1
* IMP 3: Lidocaine
* IMP 4: Sodium cloride 0.9% (=placebo)

The two injections of group 2 are IMP1 and IMP2.

After each injection the individual has to rate their pain sensation on a NRS scale and afterwards the anesthetic effect gets tested by a standardized laser application.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Local Infiltration Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Consisting of 24 individuals between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.

Intervention: Every individual receives four injections IMP1: Lidocaine and sodium bicarbonate ratio 3:1, IMP 2: Lidocaine and sodium bicarbonate ratio 9:1, IMP 3: Lidocaine, and IMP 4: Sodium cloride 0.9% (=placebo), namely two in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the four areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes.

Group Type ACTIVE_COMPARATOR

Lidocaine and sodium bicarbonate

Intervention Type DRUG

Lidocaine and sodium bicarbonate ratio 3:1

Lidocaine and sodium bicarbonate

Intervention Type DRUG

Lidocaine and sodium bicarbonate ratio 9:1

Lidocaine

Intervention Type DRUG

Lidocaine injection

Sodium cloride 0.9%

Intervention Type DRUG

Placebo

Group 2

Consisting of 24 different individuals than those belonging to Group 1. Between 18 and 75 years, able to understand German, not pregnant, with no intolerance of local anesthetics, with intact skin and no skin diseases, not prone to bleeding or taking anticoagulation or aspirine.

Intervention: Every individual receives two injections:

IMP 3 Lidocaine, and IMP 4 Sodium cloride 0.9% (=placebo), namely one in every volar forearm, and has to rate the pain associated during the injection of the fluid, not the needle stitch. Afterwards the anesthetic effect on the two areals which got injected will be checked with a palomar laser after 5, 30, 60, 90, 120 and 180 minutes.

Group Type PLACEBO_COMPARATOR

Lidocaine

Intervention Type DRUG

Lidocaine injection

Sodium cloride 0.9%

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine and sodium bicarbonate

Lidocaine and sodium bicarbonate ratio 3:1

Intervention Type DRUG

Lidocaine and sodium bicarbonate

Lidocaine and sodium bicarbonate ratio 9:1

Intervention Type DRUG

Lidocaine

Lidocaine injection

Intervention Type DRUG

Sodium cloride 0.9%

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy male or female individuals between 18 and 75 years
* able to understand and speak German
* able to follow the instructions

Exclusion Criteria

* oversensitivity to lidocaine or other local anesthetics of amide type or sulfites
* prone to bleeding, intake of aspirine or anticoagulation
* pregnancy
* skin on forearms with lesions (i.e. sunburn, wounds, eczema or other skin diseases)

* previous participation at the same study
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University hospital, Department of Dermatology

Zurich, Canton of Zurich, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LIDOBICARB

Identifier Type: -

Identifier Source: org_study_id